偶然发现的脾静脉血栓形成的临床病程与治疗:个体患者数据荟萃分析
本研究对截至2021年6月发表的随机对照试验或前瞻性研究进行个体患者数据荟萃分析,比较偶然发现与症状性脾静脉血栓形成(SVT)的临床病程,并评估抗凝治疗在偶然SVT中的安全性和有效性。共分析493例偶然SVT和493例倾向评分匹配的症状性SVT患者。偶然SVT患者接受抗凝治疗的比例较低(72.4% vs 83.6%),大出血风险相似,复发性静脉血栓栓塞风险较高,但全因死亡率较低。在偶然SVT患者中,抗凝治疗与较低的大出血、复发性VTE和全因死亡风险相关。
要点
- 偶然SVT患者大出血风险与症状性SVT相似(发生率比1.3,95%CI 0.8-2.2)。
- 偶然SVT患者复发性VTE风险高于症状性SVT(发生率比2.0,95%CI 1.2-3.3)。
- 偶然SVT患者全因死亡率低于症状性SVT(发生率比0.5,95%CI 0.4-0.7)。
核心结论
- 偶然SVT患者的大出血风险与症状性SVT相似,复发性血栓形成风险较高,但全因死亡率较低。
- 抗凝治疗在偶然SVT患者中似乎安全有效。
研究设计与样本
- 个体患者数据荟萃分析,纳入截至2021年6月发表的随机对照试验或前瞻性研究。
- 共分析493例偶然SVT患者和493例倾向评分匹配的症状性SVT患者。
主要发现
- 偶然SVT患者接受抗凝治疗的比例低于症状性SVT患者(72.4% vs 83.6%)。
- 偶然SVT与症状性SVT相比,大出血发生率比为1.3(95%CI 0.8-2.2),复发性VTE发生率比为2.0(95%CI 1.2-3.3),全因死亡率发生率比为0.5(95%CI 0.4-0.7)。
- 在偶然SVT患者中,抗凝治疗与大出血风险降低相关(HR 0.41,95%CI 0.21-0.71)。
- 在偶然SVT患者中,抗凝治疗与复发性VTE风险降低相关(HR 0.33,95%CI 0.18-0.61)。
- 在偶然SVT患者中,抗凝治疗与全因死亡风险降低相关(HR 0.23,95%CI 0.15-0.35)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical relevance and management of incidental splanchnic vein thrombosis (SVT) remain poorly defined. OBJECTIVES: The objectives of this study were to evaluate the clinical course of incidental SVT in comparison with symptomatic SVT and assess the safety and effectiveness of anticoagulant treatment in incidental SVT. METHODS: Individual patient data meta-analysis of randomized controlled trials or prospective studies published up to June 2021. Efficacy outcomes were recurrent venous thromboembolism (VTE) and all-cause mortality. The safety outcome was major bleeding. Incidence rate ratios and 95% CIs for incidental vs symptomatic SVT were estimated before and after propensity-score matching. Multivariable Cox models were used considering anticoagulant treatment as a time-varying covariate. RESULTS: In total, 493 patients with incidental SVT and 493 propensity-matched patients with symptomatic SVT were analyzed. Patients with incidental SVT were less likely to receive anticoagulant treatment (72.4% vs 83.6%). Incidence rate ratios (95% CI) for major bleeding, recurrent VTE, and all-cause mortality in patients with incidental SVT compared with symptomatic SVT were 1.3 (0.8, 2.2), 2.0 (1.2, 3.3), and 0.5 (0.4, 0.7), respectively. In patients with incidental SVT, anticoagulant therapy was associated with a lower risk of major bleeding (hazard ratio [HR] 0.41; 95% CI, 0.21 to 0.71), recurrent VTE (HR 0.33; 95% CI, 0.18 to 0.61), and all-cause mortality (HR 0.23; 95% CI, 0.15 to 0.35). CONCLUSION: Patients with incidental SVT appeared to have a similar risk of major bleeding, a higher risk of recurrent thrombosis, but lower all-cause mortality than patients with symptomatic SVT. Anticoagulant therapy seemed safe and effective in patients with incidental SVT.
引用
- Candeloro M, Valeriani E, Monreal M, et al. Clinical course and treatment of incidentally detected splanchnic vein thrombosis: an individual patient data meta-analysis. J Thromb Haemost. 2023. PMID: 36907381. doi:10.1016/j.jtha.2023.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。